Targeting PYK2, entrectinib allays anterior subcapsular cataracts in mice by regulating TGFβ2 signaling pathway

It was already known that fibrotic cataract represents a significant complication for patients who have undergone surgical lens extraction. This pathological condition involves the aberrant transformation of residual lens epithelial cells into contractile myofibroblasts through a process known as epithelial-mesenchymal transition (EMT). During this transition, cellular units lose their typical epithelial characteristics, such as the expression of the adhesion molecule E-cadherin, and begin to synthesize excessive amounts of extracellular matrix components. These components, including collagen I and fibronectin, accumulate within the lens capsule, leading to significant light scattering and visual impairment. Transforming Growth Factor Beta 2 (TGFβ2) is widely recognized as the primary cytokine driving these fibrotic changes within the aqueous humor. While various signaling mediators have been identified, the specific role of Proline-Rich Tyrosine Kinase 2 (PYK2) in lens fibrosis requires deeper investigation. This absence of evidence motivated the exploration into whether specific kinase inhibitors could interrupt the signaling cascades initiated by TGFβ2 to preserve lens clarity.

The researchers investigated the therapeutic potential of Entrectinib for mitigating fibrotic cataract development through both in vitro and in vivo models. The study sought to determine if this specific compound could suppress the expression of mesenchymal markers like alpha-smooth muscle actin (α-SMA) which are characteristic of fibrotic progression. Identifying the direct molecular target of this agent within lens epithelial cells formed a core objective of the experimental design to ensure mechanistic clarity. The team evaluated the drug's ability to interfere with both Smad-dependent and Smad-independent TGFβ2 signaling cascades, which are known to regulate the fibrotic gene program. The investigation also focused on quantifying changes in cell proliferation and migratory capacity following pharmacological treatment, as these cellular behaviors are essential for the formation of subcapsular opacities. By examining the interaction between the inhibitor and the protein Proline-Rich Tyrosine Kinase 2 (PYK2), the study aimed to establish a novel regulatory axis for ocular fibrosis. The work ultimately aimed to provide a mechanistic basis for using PYK2 inhibition as a strategy to prevent posterior or anterior subcapsular opacification in clinical settings.

The experimental protocol utilized the human lens cell line SRA 01/04 and C57BL/6J mice to model fibrotic disease states accurately. Researchers assessed cataract severity in the animal models using slit lamp examinations to visualize lens opacity and Hematoxylin and Eosin (H&E) staining to examine the histological architecture of the lens tissue. Real-time quantitative PCR (RT-qPCR) and western blotting were employed to measure the mRNA and protein expression levels of alpha-smooth muscle actin (α-SMA), collagen I, and fibronectin. Immunofluorescence assays provided spatial localization of these fibrotic markers within the lens cells, while E-cadherin levels were monitored to assess the maintenance of the epithelial phenotype. Cellular proliferation was measured using the Cell Counting Kit-8 (CCK-8) assay, while migratory behavior was tracked via wound healing and transwell assays to simulate the movement of cells across the lens capsule. To identify the binding partner of the drug, the team performed molecular docking simulations alongside Drug Affinity Responsive Target Stability (DARTS) analysis to detect protein-ligand interactions. The Cellular Thermal Shift Assay (CETSA) provided physical evidence of the interaction between the compound and the PYK2 protein by measuring changes in protein stability across a temperature gradient.

Entrectinib significantly ameliorated fibrotic cataract symptoms in the C57BL/6J mouse model and inhibited fibrotic markers in SRA 01/04 cells. At the molecular level, the treatment effectively diminished the transcriptional and translational presence of alpha-smooth muscle actin (α-SMA), collagen I, and fibronectin. Conversely, the researchers observed a substantial increase in the concentration of E-cadherin, which indicates a preservation of the epithelial phenotype and a reduction in mesenchymal transition. The drug efficiently obstructed the transduction of both the TGFβ2/Smad and TGFβ2/non-Smad signaling pathways by directly targeting the PYK2 protein, thereby preventing the activation of downstream fibrotic genes. Wound healing and transwell assays revealed that the inhibitor suppressed the migration and proliferation of lens epithelial cells, which are fundamental catalysts of cataract formation. The binding affinity confirmed through molecular docking, DARTS, and CETSA validated PYK2 as the functional target responsible for these anti-fibrotic effects. These results comprehensively illustrate that the agent acts as a potent inhibitor of the fibrotic response by modulating the intracellular signaling environment of the lens.

The findings suggest that targeting PYK2 with Entrectinib offers a viable pharmacological approach to managing anterior subcapsular cataracts and other fibrotic ocular conditions. By blocking the dual TGFβ2 signaling pathways, this intervention lessens the activation of the epithelial-mesenchymal transition (EMT) process that leads to lens opacification. The study highlights the potential for repurposing existing kinase inhibitors to address unmet needs in ocular fibrotic diseases where no clinical medications currently exist. Future clinical applications might involve using the compound as a post-operative treatment to prevent secondary cataract formation in patients undergoing lens replacement surgery. The researchers conclude that the modulation of the PYK2/TGFβ2 axis represents a promising therapeutic window for lens transparency maintenance and the prevention of visual loss. These results provide a foundation for further human trials to evaluate the safety and efficacy of this compound in ophthalmic patients. The study underscores the importance of identifying specific kinase targets like PYK2 to develop precise interventions for complex fibrotic disorders of the eye.